Pressure
BioSciences (OTCQB: PBIO), a leader in the development and sale of
broadly enabling, pressure-based technology and products to the worldwide life
sciences and other industries, has developed a revolutionary CBD processing
system, the BaroShear K45, which effectively solves the water solubility issue
found in most of today’s oil-based CBD products. An article discussing the company
reads, “Development of the BaroShear K45 system began following the company’s
in-depth analysis of the CBD market, which showed a common, yet critical
production issue facing CBD manufacturers – the poor water solubility of
today’s oil-based CBD products means that the beneficial properties of CBD are
inadequately available for absorption in the body. . . . ‘After much diligence
and analysis, we concluded that we have the expertise and experience to
successfully address this critical issue,’ Richard T. Schumacher, president and
CEO of PBIO, stated in an August 2019 shareholder report (http://ibn.fm/Ym0dG).
‘Consequently, we pulled significant hours away from many of our staff over the
past few months and had them focus on the development of an instrument system –
based on our patented UST platform – that would increase the water-solubility,
and thus the absorption, of CBD Oil. We succeeded; the result of that success
is the BaroShear K45 processing system.’”
To view the full article, visit http://ibn.fm/hUGvv
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and to (ii) prepare higher quality, homogenized, extended shelf-life or
room temperature stable low-acid liquid foods that cannot be effectively
preserved using existing non-thermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
